Subscribe to Newsletter

Business Practice

Business & Regulation Biosimilars

Brace for Biosimilars!

| Jeff Baldetti

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Business & Regulation Business Practice

Done Deal: Creating Anti-COVID-19 Equity

| Maryam Mahdi

Medicines Patent Pool has joined forces with over 30 generic manufacturers to help ensure access to anti-COVID-19 medicines for all.

Business & Regulation Trends & Forecasts

March’s Top Biopharma Headlines

| Stephanie Vine

The Medicine Maker’s round up of the top news stories in the pharma industry in March.

Business & Regulation Technology and Equipment

The 360 Virtual Tour

| Stephanie Vine

We find out how technology is enabling remote inspections in the pharma industry.

Business & Regulation Standards & Regulation

An Ode to Flexible Cleanroom Furniture

| Sue Springett

Reconfigure. Redefine. Why modular cleanroom furniture is essential for a changing pharmaceutical market.

Business & Regulation Business Practice

What’s in a Name?

| Maryam Mahdi

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

Business & Regulation Standards & Regulation

The (DILI) Model of Success

| Maryam Mahdi

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

Business & Regulation Business Practice

Time Will Always Tell

| Maryam Mahdi

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

Discovery & Development Business Practice

“We Want to Return to the Lab”: How the Russian Invasion Has Disrupted Drug Discovery in Ukraine

| Angus Stewart

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.

Business & Regulation Business Practice

What it takes to enable tech transfer partnerships

| Thomas Cueni

IFPMA’s Director-General, Thomas Cueni, outlines how companies worldwide can foster long-term tech transfer partnerships.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register